950 — Lees Pharmaceutical Holdings Share News
0.000.00%
Last trade - 00:00- HK$624.17m
- HK$438.96m
- HK$1.44bn
Brief: Lee's Pharmaceutical Says Obtained Drug Marketing Authorisation Of Azilsartan Tablets From NMPA On Sept 20
Brief: Lee's Pharmaceutical Says Qtrly Profit Attributable HK$8.2 Mln
Brief: Lee's Pharmaceutical Says Got Global License Of Surfaxintm, Surfaxin LSTM And Aerosurftm
Windtree surges on licensing deal for lung disease therapy
Brief: Lee's Pharmaceutical Holdings Ltd Sees Net Profit Attributable Of Between Hk$25 Million And Hk$30 Million For Six Months
Brief: Unicycive Announces Exclusive License And Development Agreement With Lee’S Pharmaceutical Holdings Limited For Renazorb In China And Certain Other Asian Markets
Brief: Lee's Pharmaceutical Says Drug Registration Certificate For Teglutik Obtained From China's Nmpa
Brief: Lee's Pharmaceutical Says Drug Registration Certificate For Natulan Obtained From China's Nmpa
Brief: Lee's Pharmaceutical FY Profit Attributable HK$1.99 Bln
Brief: Lee's Pharmaceutical Holdings Says Qtrly Revenue Of HK$368.3 Mln
Brief: Lee's Pharmaceutical Says NDA Of Socazolimab Submitted, Accepted By China's NMPA
Brief: Lee's Pharmaceutical Obtained Approval From CDE Of China's NMPA For Socazolimab
Brief: Lee's Pharmaceutical Reports Qtrly Profit Attributable of HK$2.11 Bln
Brief: Lee's Pharmaceutical Holdings Ltd Sees Increase In Net Profit Attributable Six Months
Brief: Lee's Pharmaceutical Says Entered License Agreement With Asahi Kasei Pharma Corp
Brief: Lee's Pharmaceutical Says Unit Shall Advance A Loan Of US$3 Mln To China Oncology Focus Ltd
Brief: Lee's Pharmaceutical Says Drug Registration Certificate Has Been Obtained From NMPA
Brief: Lee's Pharmaceutical Says Stock Exchange Has Granted Approval For Listing Of Zhaoke Ophthalmology Shares
Lee's Pharmaceutical's spinoff unit Zhaoke falls in Hong Kong debut